loader2
Login Open ICICI 3-in-1 Account

Suven Life Sciences Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Suven Life Sciences Ltd. 11 Nov 2025 12:33 PM

Q2FY26 Quarterly Result Announced for Suven Life Sciences Ltd.

Healthcare Services company Suven Life Sciences announced Q2FY26 results

  • Revenue: Rs 46.97 million against Rs 66.09 million during Q2FY25.
  • PAT: Rs -773.10 million against Rs -496.44 million during Q2FY25.
  • EPS: Rs -3.48 for Q2FY26.
  • Clinical development pipeline:
    • SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of calander 2026.
    • SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy by end of fiscal 2026.
    • SUVN-911 (Ropanicant) – Ongoing Phase 2B clinical study in USA and expected completion by end of calander 2026.
    • SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition during 2026.
    • SUVN-I6107 – Ongoing Phase 1 study for establishing safety and pharmacokinetics of the molecule. Anticipated completion by fiscal 2026.

Result PDF

Healthcare Services company Suven Life Sciences announced Q1FY26 results

  • Revenue: Rs 24.67 million compared to Rs 50.14 million during Q1FY25.
  • PAT: Rs -515.17 million compared to Rs -280.40 million during Q1FY25.
  • EPS: Rs -2.36 for Q1FY26.

Result PDF

Healthcare Services company Suven Life Sciences announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue: Rs 26.90 million compared to Rs 66.68 million during Q4FY24.
  • PAT: Rs -439.45 million compared to Rs -265.41 million during Q4FY24.
  • EPS: Rs -2.02 compared to Rs -1.22 million during Q4FY24.

FY25 Financial Highlights:

  • Revenue: Rs 175.53 million compared to Rs 328.23 million during FY24.
  • PAT: Rs -1,607.45 million compared to Rs -1,050.76 million during FY24.
  • EPS: Rs -7.37 compared to Rs -4.82 million during FY24.

Result PDF

Healthcare Services company Suven Life Sciences announced Q3FY25 results

  • Revenue: Rs 32.40 million compared to Rs 85.16 million during Q3FY24.
  • PAT: Rs -391.17 million compared to Rs -417.65 million during Q3FY24.
  • EPS: Rs -1.79 for Q3FY25.
  • Clinical development pipeline:
    • SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of FY26.
    • SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy in Q1FY26.
    • SUVN-911 (Ropanicant) – Phase 2A open label study for Major Depressive Disorder in USA successfully completed. Preparing to start Phase 2B clinical study in Q1FY26.
    • SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition in MDD during FY26.
    • SUVN-I6107 – Phase 1 study initiated during FY25 is continuing for establishing safety and pharmacokinetics of the molecule. 

Result PDF

Pharmaceuticals company Suven Life Sciences announced Q2FY25 results

  • Revenue: Rs 66.09 million, compared to Rs 82.01 million during Q2FY24.
  • PAT/Loss: Rs -496.44 million, compared to Rs 126.80 million during Q2FY24.
  • EPS: Rs -2.27, compared to Rs -0.58 during Q2FY24.

Result PDF

Pharmaceuticals company Suven Life Sciences announced Q4FY24 & FY24 results:

Financial Highlights:

Suven Life Sciences reported a revenue of Rs 66.7 million in Q4FY24, showing a decline compared to the previous quarter's revenue of Rs 85.2 million.

The company experienced a net loss after tax of Rs 265.4 million in Q4FY24, and a cumulative annual loss of Rs 1,050.8 million for the year FY24.

Expenses Breakdown:

R&D and Operational expenses accounted for a significant portion of the total expenses, posting Rs 326.7 million for the quarter and Rs 1,397 million for the year.

Depreciation and Amortisation costs were recorded at Rs 15.1 million for the quarter, while Finance costs were relatively low at Rs 0.3 million.

Exceptional Items: 

An exceptional item included in the financials reflects an insurance claim received by the company, amounting to Rs 10.0 million.

Comprehensive Income: 

The total comprehensive income for the quarter reflects a loss of Rs 267.4 million after factoring in other comprehensive income, which was a loss of Rs 2.0 million.

Stock and Earnings per Share:

The paid-up equity capital stood constant at Rs 218.1 million for the reported periods, while the Earnings Per Share (EPS) showed a loss of Rs 1.2 for the quarter and a loss of Rs 4.8 for the full year.

Result PDF

Pharmaceuticals firm SUVEN Life Sciences declares Q3FY22 result:

  • Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.
  • The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.
  • Clinical development pipeline:
    • SUVN-502 (Masupirdine) – Completed phase 2 study on Alzheimer’s in USA and to be initiated phase 3 study for new indication on Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; expected completion by end of the year 2024. Expected site activation by end of March 2022 and expected patient enrollment during the quarter April – June 2022.
    • SUVN-G3031 (Samelisant) – Ongoing phase 2 study on Narcolepsy in North America; expected completion by FY2023. 109 patients randomized, 82 completed of the total expected 195 patients (including 18 replacements).
    • SUVN-D4010 (Usmarapride) – Completed phase 1 study, ready for phase 2
    • SUVN-911 (Ropanicant) – Completed phase 1 study, ready for phase 2
  • Since last reporting period, the Company has been granted 19 patents for its innovative drug discovery covering ARIPO, Brazil, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, Singapore, Sri Lanka, South Africa and USA.

 

Result PDF

Highlights

  • Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.
  • The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.
  • Clinical development pipeline:
    • SUVN-502 (Masupirdine) – Completed phase 2 study on Alzheimer’s in USA and to be initiated phase 3 study on Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; expected completion by the year end 2024
    • SUVN-G3031 (Samelisant) – Ongoing phase 2 study on Narcolepsy in North America; expected completion by the year end 2022
    • SUVN-D4010 (Usmarapride) – Completed phase 1 study, ready for phase 2
    • SUVN-911 (Ropanicant) – Completed phase 1 study, ready for phase 2 
  • Since last reporting period, the Company has been granted 13 patents for its innovative drug discovery covering ARIPO, China, Eurarisia, Hong Kong, Macao, South Africa, Sri Lanka, and USA.

 

 

 

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app